BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced liver disease secondary to ezetimibe. World J Gastroenterol 2008; 14(32): 5098-5099 [PMID: 18763297 DOI: 10.3748/wjg.14.5098]
URL: https://www.wjgnet.com/1007-9327/full/v14/i32/5098.htm
Number Citing Articles
1
Željko Reiner. Management of patients with familial hypercholesterolaemiaNature Reviews Cardiology 2015; 12(10): 565 doi: 10.1038/nrcardio.2015.92
2
M V. Zykov. The problem of safety of lipid-lowering therapyKardiologiia 2019; 59(5S): 13 doi: 10.18087/cardio.2505
3
Rgia A. Othman, Semone B. Myrie, David Mymin, Louise S. Merkens, Jean-Baptiste Roullet, Robert D. Steiner, Peter J.H. Jones. Ezetimibe Reduces Plant Sterol Accumulation and Favorably Increases Platelet Count in SitosterolemiaThe Journal of Pediatrics 2015; 166(1): 125 doi: 10.1016/j.jpeds.2014.08.069
4
Firas J. Al Badarin, Iftikhar J. Kullo, Stephen L. Kopecky, Randal J. Thomas. Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?Mayo Clinic Proceedings 2009; 84(4): 353 doi: 10.1016/S0025-6196(11)60545-4
5
Keshav Kumar Gupta, Shair Ali, Ranjodh Singh Sanghera. Pharmacological Options in Atherosclerosis: A Review of the Existing EvidenceCardiology and Therapy 2019; 8(1): 5 doi: 10.1007/s40119-018-0123-0
6
Yoonkyung Chang, Soojeong Eom, Minjeong Kim, Tae-Jin Song. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative ReviewMedicina 2023; 59(4): 776 doi: 10.3390/medicina59040776
7
Dina Halegoua-De Marzio, Victor J. Navarro. Drug-Induced Liver Disease2013; : 519 doi: 10.1016/B978-0-12-387817-5.00029-7
8
Venice Du Pont, Richard K Plemper, Matthias J Schnell. Status of antiviral therapeutics against rabies virus and related emerging lyssavirusesCurrent Opinion in Virology 2019; 35: 1 doi: 10.1016/j.coviro.2018.12.009
9
Current awareness: Pharmacoepidemiology and drug safetyPharmacoepidemiology and Drug Safety 2009; 18(2) doi: 10.1002/pds.1645
10
Firas J. Al Badarin, Iftikhar J. Kullo, Stephen L. Kopecky, Randal J. Thomas. Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?Mayo Clinic Proceedings 2009; 84(4): 353 doi: 10.4065/84.4.353
11
Željko Reiner. Combined therapy in the treatment of dyslipidemiaFundamental & Clinical Pharmacology 2010; 24(1): 19 doi: 10.1111/j.1472-8206.2009.00764.x
12
Ryan C. Van Woerkom, Douglas G. Adler. Letter to the EditorJournal of Clinical Lipidology 2010; 4(4): 314 doi: 10.1016/j.jacl.2010.03.075
13
Michael Demyen, Kawtar Alkhalloufi, Nikolaos T. Pyrsopoulos. Lipid-Lowering Agents and HepatotoxicityClinics in Liver Disease 2013; 17(4): 699 doi: 10.1016/j.cld.2013.07.016
14
Retrospective Study on Hepatic Injury of Ezetimibe and Simvastatin Combination vs. SimvastatinJournal of Korean Society of Health-System Pharmacists 2013; 30(6): 523 doi: 10.32429/jkshp.2013.30.6.002
15
Tharsan Kanagalingam, Julieta Lazarte, David K.H. Wong, Robert A. Hegele. Liver Injury Associated With Ezetimibe MonotherapyCJC Open 2021; 3(2): 195 doi: 10.1016/j.cjco.2020.09.018
16
Silje Bergland Ellingsen, Elisabet Nordmo, Knut Tore Lappegård. Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With EzetimibeClinical Medicine Insights: Case Reports 2017; 10 doi: 10.1177/1179547617731375
17
Fawaz Almutairi, Theresa C. Peterson, Michele Molinari, Mark J. Walsh, Ian Alwayn, Kevork M. Peltekian. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemiaLiver Transplantation 2009; 15(5): 504 doi: 10.1002/lt.21710